entertainment -WSS

entertainment

author：hotspot 2025-09-30 18:08:20 - browse：725

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Medicare to cover more brain scans related to Alzheimer’s drugs

WSS

Female surgeons have lower rates of long

Female surgeons have lower rates of long

What's changing in Medicare's open enrollment this year?

Mass General totes up its waste in a move to tackle climate change

Life sciences deals on track to hit lowest point since 2017

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

entertainment

entertainment

hotspot

Psychedelics group wrestles with new pharma identity

STAT Readout Newsletter: Today in biotech, life science news

At least 13 dead in Texas as scorching temps continue

Massive project maps cells in human brain in unprecedented detail

Peter Hotez and the public health issue of online harassment

Life sciences deals on track to hit lowest point since 2017

Duchenne breakthrough therapy leaves behind pioneering families

Better Therapeutics data on benefit with GLP

Hepatitis C has a cure — but many Americans still lack access to it

Hospitals struggle to profit from CAR

hotspot

Mass General totes up its waste in a move to tackle climate change

There’s no way to know how good AI health technologies are

Massive project maps cells in human brain in unprecedented detail

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

DeSantis talks Trump, trans issues and 'what wokeness is'

Eight reasons why you should get an updated Covid vaccine

entertainment

leisure time

Wikipedia

focus